Monte Rosa Therapeutics Inc (GLUE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Monte Rosa Therapeutics Inc (GLUE) has a cash flow conversion efficiency ratio of -0.168x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-81.48 Million) by net assets ($485.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see GLUE stock market capitalisation for the company's overall valuation and market capitalisation.
Monte Rosa Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Monte Rosa Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Monte Rosa Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Monte Rosa Therapeutics Inc ranked by their cash flow conversion efficiency. Explore Monte Rosa Therapeutics Inc (GLUE) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shinva Medical Instrument Co Ltd
SHG:600587
|
-0.003x |
|
Shanghai Electric Group Company Limited
F:USR
|
0.061x |
|
KBC Corporation Ltd
SHG:688598
|
-0.008x |
|
Wuxi Online Offline Communication Information Technology Co. Ltd.
SHE:300959
|
N/A |
|
Suzhou New District Hi Tech Industrial Co Ltd
SHG:600736
|
0.034x |
|
WuXi Xinje Electric Co Ltd
SHG:603416
|
0.001x |
|
Jiajia Food Group Co Ltd
SHE:002650
|
-0.002x |
|
Guardian Capital Group Ltd. Cl.A Nv (GCG-A.TO
TO:GCG-A
|
0.049x |
Annual Cash Flow Conversion Efficiency for Monte Rosa Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Monte Rosa Therapeutics Inc from 2019 to 2025. View Monte Rosa Therapeutics Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $233.06 Million | $-22.80 Million | -0.098x | -151.93% |
| 2024-12-31 | $222.94 Million | $42.00 Million | 0.188x | +177.09% |
| 2023-12-31 | $179.25 Million | $-43.80 Million | -0.244x | +28.27% |
| 2022-12-31 | $271.41 Million | $-92.47 Million | -0.341x | -99.44% |
| 2021-12-31 | $347.51 Million | $-59.36 Million | -0.171x | -136.11% |
| 2020-12-31 | $-48.73 Million | $-23.05 Million | 0.473x | -6.90% |
| 2019-12-31 | $-12.15 Million | $-6.17 Million | 0.508x | -- |
About Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment… Read more